Endonovo Therapeutics Company Insiders
| ENDV Stock | USD 0.0002 0.0001 100.00% |
Endonovo Therapeutics employs about 7 people. The company is managed by 4 executives with a total tenure of roughly 13 years, averaging almost 3.0 years of service per executive, having 1.75 employees per reported executive. Recap of Endonovo Therapeutics' management performance can provide insight into the venture performance.
| Alan Collier Chairman Chairman, CEO, Principal Accounting Officer, Interim CFO and Secretary |
Endonovo |
Endonovo Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (1.0992) % which means that it has lost $1.0992 on every $100 spent on assets. This is way below average. Endonovo Therapeutics' management efficiency ratios could be used to measure how well Endonovo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Endonovo Therapeutics Workforce Comparison
Endonovo Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 667. Endonovo Therapeutics claims roughly 7.0 in number of employees contributing just under 2% to equities under Health Care industry.
Endonovo Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Endonovo Therapeutics Price Series Summation is a cross summation of Endonovo Therapeutics price series and its benchmark/peer.
Endonovo Therapeutics Notable Stakeholders
An Endonovo Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Endonovo Therapeutics often face trade-offs trying to please all of them. Endonovo Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Endonovo Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Alan Collier | Chairman, CEO, Principal Accounting Officer, Interim CFO and Secretary | Profile | |
| Ira Weisberg | Pres Division | Profile | |
| Don Calabria | VP Operations | Profile | |
| Garry Kann | Head Devel | Profile |
About Endonovo Therapeutics Management Performance
The success or failure of an entity such as Endonovo Therapeutics often depends on how effective the management is. Endonovo Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Endonovo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Endonovo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California. Endonovo Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Please note, the imprecision that can be found in Endonovo Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Endonovo Therapeutics. Check Endonovo Therapeutics' Beneish M Score to see the likelihood of Endonovo Therapeutics' management manipulating its earnings.
Endonovo Therapeutics Workforce Analysis
Traditionally, organizations such as Endonovo Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Endonovo Therapeutics within its industry.Endonovo Therapeutics Manpower Efficiency
Return on Endonovo Therapeutics Manpower
| Revenue Per Employee | 10.4K | |
| Revenue Per Executive | 18.3K | |
| Net Loss Per Employee | 443.6K | |
| Net Loss Per Executive | 776.2K |
Additional Tools for Endonovo Pink Sheet Analysis
When running Endonovo Therapeutics' price analysis, check to measure Endonovo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Endonovo Therapeutics is operating at the current time. Most of Endonovo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Endonovo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Endonovo Therapeutics' price. Additionally, you may evaluate how the addition of Endonovo Therapeutics to your portfolios can decrease your overall portfolio volatility.